TAPO in first‐line osimertinib therapy and continuation of osimertinib

por Mimura, Chihiro, Kaneshiro, Kazumi, Fujimoto, Shodai, Dokuni, Ryota, Iwamoto, Natsuhiko, Matsumura, Kanoko, Hatakeyama, Yukihisa, Kono, Yuko, Tachihara, Motoko
Publicado 2022

Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy

por Okamoto, Mariko, Kim, Young Hak, Ouchi, Aiko, Yamaoka, Takashi, Iwamoto, Natsuhiko, Iwatsubo, Shigeaki, Matsumura, Kanoko, Nakamura, Miho, Kin, Yasuo, Shiina, Yoshitaka, Funada, Yasuhiro
Publicado 2021

Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer

por Fukuda, Kiyoko, Katsurada, Naoko, Kawa, Yoshitaka, Satouchi, Miyako, Kaneshiro, Kazumi, Matsumoto, Masataka, Takamiya, Rei, Hatakeyama, Yukihisa, Dokuni, Ryota, Matsumura, Kanoko, Katsurada, Masahiro, Nakata, Kyosuke, Yoshimura, Sho, Tachihara, Motoko
Publicado 2023